Furthermore, a glucocorticoid dexamethasone treatment, in severe COVID-19 patients, is known to induce anti-inflammatory AnxA1 and also enhances its translocation to cell membrane, could reduce the membrane deposition of AnxA2, making it unavailable for the virus entry and replication [97]. Here, ANXA2 is linked to COVID-19.